Oxygen Biotherapeutics, Inc. (OXBO.OB) Licenses Its Glucose Biosensor Devices
Oxygen Biotherapeutics, Inc. announced that a license agreement for its glucose biosensor technology has been reached with Glucometrics, Inc. The biosensor measures glucose levels in diabetes patients at accuracy levels higher than FDA standards require, a company news release states. Glucometrics now has a license for all applications involving measurement and monitoring of glucose levels. In return, Oxygen Biotherapeutics receives stock in Glucometrics and royalties based on worldwide net revenues from products derived from the licensed technology. “I am proud to announce this major milestone in our corporate history with our first-ever license agreement,” said OXBO Chairman and CEO Chris…